Across TCGA pan-cancer cohorts, RASGEF1A mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RASGEF1A data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RASGEF1A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RASGEF1A expression acts as an unfavorable survival marker.

GBM are the cancer types where RASGEF1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.159	0.981	.036	10	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: RASGEF1A tumor-vs-normal RNA expression · all RASGEF1A data types